Comparison · NCT04875195-deaths
Relapsed or Refractory Classical Hodgkin's Lymphoma (rrcHL) vs Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL): deaths from any cause
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Relapsed or Refractory Classical Hodgkin's Lymphoma (rrcHL) vs Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL): deaths from any cause. Trial comparisons, record NCT04875195-deaths. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04875195-deaths
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.15 | 0.081 | 0.261 | wilson | |
| Risk in group 2 | 0.5 | 0.188 | 0.812 | wilson | |
| Risk difference, group 1 minus group 2 | -0.35 | -0.67 | -0.0184 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.3 | 0.11 | 0.817 | log | |
| Odds ratio, group 1 over group 2 | 0.176 | 0.0307 | 1.02 | log | |
Number needed to treat, for one fewer death from any cause on Relapsed or Refractory Classical Hodgkin's Lymphoma (rrcHL) than on Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) | 2.86 | 1.49 | 54.3 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Relapsed or Refractory Classical Hodgkin's Lymphoma (rrcHL) | Participants with rrcHL received pembrolizumab 400 mg as an intravenous (IV) infusion on Day 1, then every six weeks (Q6W) up to 18 doses. | 9 | 60 | EG000 |
| Group 2 | Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) | Participants with rrPMBCL received pembrolizumab 400 mg as an intravenous (IV) infusion on Day 1, then every six weeks (Q6W) up to 18 doses. | 3 | 6 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, all-cause mortality
- Time frame
- Up to approximately 30 months
Source ClinicalTrials.gov
Trial
- Title
- A Study of Pembrolizumab (MK-3475) in Relapsed or Refractory Classical Hodgkin's Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (MK-3475-B68)
- NCT number
- NCT04875195
- Phases
- PHASE2
- Conditions
- Hodgkin's Lymphoma, Primary Mediastinal Large B-cell Lymphoma (PMBCL)
- Interventions
- Pembrolizumab
- Lead sponsor
- Merck Sharp & Dohme LLC
- Results first posted
- 2025-02-10
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT04875195?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT04875195-deaths